Empirical data capturing participants’ experiences in preclinical Alzheimer's disease (AD) trials are limited. We examined participant responses on a Research Satisfaction Survey (RSS) from the Anti‐Amyloid Treatment in Asymptomatic AD Study.
Marina Ritchie, K. Hussen, O. Langford et al.· Alzheimer's & Dementia· 0 citations
SOMI’s risk profile in A4 was similar to prior findings in observational cohorts, and provides a low-cost, non-invasive enrichment tool for identifying individuals at risk for early cognitive decline in secondary prevention trials.
Priyanka Kumari, R. Lipton, A. Aschenbrenner et al.· The journal of prevention of...· 0 citations
These findings uncover protein signatures that reflect underlying AD biology and provide a foundation for stage-specific biomarkers and therapeutic targeting, with important implications for patient stratification and personalized intervention strategies.
Saima Rathore, E. Dammer, Anantharaman Shantaraman et al.· Molecular Neurodegeneration· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.